title: Enhanced pretreatment CD25 expression on peripheral blood CD4+ T cell predicts shortened survival in acute myeloid leukemia patients receiving induction chemotherapy.
abstract: BACKGROUND
  Recently, identification of CD25 (interleukin-2 receptor alpha) expression on leukemic blasts was correlated to early treatment failure and unfavorable outcome in acute myeloid leukemia (AML) patients. Here we wished to determine whether quantification of CD25 on peripheral blood CD4+ T cells could improve prognostication in newly diagnosed AML patients.
  
  
  METHODS
  The mean fluorescence intensity (MFI) of CD25 expression and frequencies of peripheral blood CD4+ T cells with varying levels of CD25 and CD127 expression were assessed by flow cytometry in all studied individuals.
  
  
  RESULTS
  Using univariate (unadjusted) and multivariate (adjusted) analyses we demonstrated that detection of high pretreatment CD25 expression on circulating CD4+ T cells was associated with significantly decreased survival rate of AML patients subjected to standard induction chemotherapy. These associations held true for both entire group of analyzed AML patients and different subgroups of patients identified by presence or absence of favorable and adverse molecular prognostic factors.
  
  
  CONCLUSIONS
  Our data indicate that quantification of CD25 expression on peripheral blood CD4+ T cells could become a novel, easily accessible method of shortened survival prognostication of AML patients subjected to standard cytotoxic therapy.
authors.affiliation: Department of Hematology, Medical University of Bialystok, Białystok, Poland. Electronic address: lbolkun@gmail.com.
authors.forename: Łukasz
authors.initials: Ł
authors.lastname: Bołkun
authors.affiliation: Department of Hematological Diagnostics, Medical University of Bialystok, Białystok, Poland. Electronic address: mrusak@umb.edu.pl.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Rusak
authors.affiliation: Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Białystok, Poland. Electronic address: andrzej.eljaszewicz@umb.edu.pl.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Eljaszewicz
authors.affiliation: Clinical Statistics - Interdisciplinary Tumor Center, Heidelberg University Medical Center Mannheim, Mannheim, Germany. Electronic address: lothar.pilz@medma.uni-heidelberg.de.
authors.forename: Lothar
authors.initials: L
authors.lastname: Pilz
authors.affiliation: Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Białystok, Poland. Electronic address: urszula.radzikowska@umb.edu.pl.
authors.forename: Urszula
authors.initials: U
authors.lastname: Radzikowska
authors.affiliation: Department of Hematology, Medical University of Bialystok, Białystok, Poland. Electronic address: izabelalap@gmail.com.
authors.forename: Izabela
authors.initials: I
authors.lastname: Łapuć
authors.affiliation: Department of Hematology, Medical University of Bialystok, Białystok, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Łuksza
authors.affiliation: Department of Hematological Diagnostics, Medical University of Bialystok, Białystok, Poland. Electronic address: mdabrows@umb.edu.pl.
authors.forename: Milena
authors.initials: M
authors.lastname: Dąbrowska
authors.affiliation: Department of Allergology and Internal Medicine, Medical University of Bialystok, Białystok, Poland. Electronic address: alergol@umb.edu.pl.
authors.forename: Anna
authors.initials: A
authors.lastname: Bodzenta-Łukaszyk
authors.affiliation: Department of Hematology, Medical University of Bialystok, Białystok, Poland. Electronic address: hem@umb.edu.pl.
authors.forename: Janusz
authors.initials: J
authors.lastname: Kłoczko
authors.affiliation: Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Białystok, Poland; Department of Allergology and Internal Medicine, Medical University of Bialystok, Białystok, Poland. Electronic address: Marcin.Moniuszko@umb.edu.pl.
authors.forename: Marcin
authors.initials: M
authors.lastname: Moniuszko
mesh_terms: D000328:Adult; D000368:Aged; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism*; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D060828:Induction Chemotherapy / Q000401:mortality* / Q000639:trends*; D053645:Interleukin-2 Receptor alpha Subunit / Q000096:biosynthesis*; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000378:metabolism* / Q000401:mortality*; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D015996:Survival Rate / Q000639:trends
chemical_list: C508017:IL2RA protein, human; D053645:Interleukin-2 Receptor alpha Subunit
keywords: CD25; Myeloid leukemia; Prognostication; T-cell mediated immunity